Envisagenics co-founders Maria Luisa Pineda (L) and Martin Akerman

Ex­clu­sive: In­spired by Spin­raza, start­up rais­es $25M for can­cer drug tar­gets cre­at­ed by al­ter­na­tive RNA splic­ing

En­vis­agen­ics, a start­up found­ed by sci­en­tists from Cold Spring Har­bor Lab­o­ra­to­ry, has raised a $25 mil­lion se­ries B round to de­vel­op drugs for can­cer and …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.